Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that five abstracts highlighting the latest preclinical results from its pipeline programs have been selected for presentations at the 2025 American Association of Cancer Research Annual Meeting (AACR), taking place April 25-30, 2025, in Chicago, Illinois, USA.
The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, EED inhibitor APG-5918, and IAP antagonist AS03157.
The AACR Annual Meeting is the critical driver of progress against cancer, the place where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share and discuss the latest breakthroughs. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting showcases cutting-edge cancer science and medicine.
The five preclinical abstracts from Ascentage Pharma include:
Olverembatinib (HQP1351) in combination with lisaftoclax (APG-2575) overcomes venetoclax resistance in preclinical models of acute myeloid leukemia (AML)
- Abstract#: 5652
- Session Category: Experimental and Molecular Therapeutics
- Session Title: Novel Antitumor Agents 3
- Date and Time: Tuesday April 29, 2025, 2:00 PM – 5:00 PM, Central Time (Wednesday April 30, 2025, 3:00 AM – 6:00 AM, Beijing Time)
Effects of olverembatinib (HQP1351) in combination with BCL-2 inhibitor lisaftoclax (APG-2575) in T-cell acute lymphoblastic leukemia (T-ALL)
- Abstract#: 5648
- Session Category: Experimental and Molecular Therapeutics
- Session Title: Novel Antitumor Agents 3
- Date and Time: Tuesday April 29, 2025, 2:00 PM – 5:00 PM, Central Time (Wednesday April 30, 2025, 3:00 AM – 6:00 AM, Beijing Time
Embryonic ectoderm development protein (EED) inhibitor APG-5918 exhibits potent antitumor activity and synergizes with androgen receptor (AR) inhibitor enzalutamide in preclinical prostate cancer (PCa) models
- Abstract#: 446
- Session Category: Experimental and Molecular Therapeutics
- Session Title: Epigenetic Targets
- Date and Time: Sunday April 27, 2025, 2:00 PM – 5:00 PM, Central Time (Monday April 28, 2025, 3:00 AM – 6:00 AM, Beijing Time)
APG-2449, a novel focal adhesion kinase (FAK) inhibitor, enhances the antitumor activity of chemotherapy in preclinical models of small-cell lung cancer (SCLC) with activated FAK
- Abstract#: 1679
- Session Category: Experimental and Molecular Therapeutics
- Session Title: Drug Combination Strategies for Cancer Treatment
- Date and Time: Monday April 28, 2025, 9:00 AM – 12:00 PM, Central Time (Monday April 28, 2025, 10:00 PM – 1:00 AM the next day, Beijing Time)
Discovery of AS03157 as a highly potent and orally active antagonist of inhibitor of apoptosis proteins (IAPs)
- Abstract#: 5651
- Session Category: Experimental and Molecular Therapeutics
- Session Title: Novel Antitumor Agents 3
- Date and Time: Tuesday April 29, 2025, 2:00 PM – 5:00 PM, Central Time (Wednesday April 30, 2025, 3:00 AM – 6:00 AM, Beijing Time)
Olverembatinib is an investigational drug and is not approved in the U.S.
About Ascentage Pharma
Ascentage Pharma is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in hematological malignancies. Ascentage Pharma has been listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK since October 2019 and has also been listed on the Nasdaq Global Market under the ticker symbol “AAPG” since January 2025.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.